StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.60−0.03 (-1.84%)

Close on Nov 16, 2026Market cap $4.06MP/E –Yield –

Alaunos Therapeutics, Inc. saw revenue fall 50.0% to $3.00K over the twelve months to Jun 30, 2026. Free cash flow was -$2.97M. At the latest close the market valued the company at $4.06M.

Revenue
$3.00K
-50.0% vs. a year earlier
Operating income
-$4.06M
TTM Q2 2026
Free cash flow
-$2.97M
FY2025
EPS, diluted
-$1.95
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$4.06M
P/E ratio
–
Price to sales
1354.92
Price to book
6.23
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$3.00K
Net income
-$4.01M
EPS, diluted
-$1.95
Free cash flow
-$2.97M
Book value per share
$0.27
Diluted shares
2M

Trading

Previous close
$1.63
Open
$1.59
Day's range
$1.58 – $1.68
Volume
61,521
Average volume (20 days)
680,560
52-week range
$0.72 – $4.50
RSI (14 days)
44.2
Volatility (1 year)
214.3%
Relative volume
0.01×

Market cap history

Month-end market cap since 2010, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodTCRTS&P 500DifferenceTCRT per yearS&P 500 per year
1 month-39.2%-3.1%−36.1 pts
3 months-17.1%-4.5%−12.6 pts
Year to date-50.5%+9.4%−59.8 pts
1 year-46.1%+11.3%−57.4 pts
3 years-84.8%+70.4%−155.2 pts-46.6%+19.4%
5 years-99.2%+68.6%−167.8 pts-62.3%+11.0%
10 years-99.8%+297.7%−397.5 pts-47.6%+14.8%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$3.00K-50.0% YoY

Operating income

-$4.06M

Net income

-$4.01M

EPS, diluted

-$1.95

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Alaunos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Alaunos Therapeutics

Pharmaceutical Preparations

Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical enterprise concentrating on the discovery and development of orally administered small-molecule treatments for obesity and metabolic conditions, including metabolic dysfunction-associated steatotic liver disease. The company's lead therapeutic candidate, ALN1003, utilizes a differentiated, non-hormonal, and non-incretin mechanism of action intended to provide an alternative or complementary option to hormone-based incretin therapies. Alaunos previously operated as a clinical-stage oncology biotechnology firm focused on developing adoptive T-cell receptor engineered cell therapies before pivoting away from that portfolio.

Company profile, executives and history

Alaunos Therapeutics stock: common questions

What is Alaunos Therapeutics's stock price?

TCRT closed at $1.60 on Nov 16, 2026, down 1.84% on the day. Over the past 52 weeks it traded between $0.72 and $4.50.

What is Alaunos Therapeutics's market cap?

Alaunos Therapeutics was worth $4.06M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is TCRT's P/E ratio?

Alaunos Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.95), so it has no meaningful P/E ratio.

How much revenue does Alaunos Therapeutics make?

Alaunos Therapeutics reported revenue of $3.00K for the twelve months to Jun 30, 2026, down 50.0% from a year earlier.

Does Alaunos Therapeutics pay a dividend?

No. Alaunos Therapeutics has not paid a cash dividend over the last twelve months.

How has TCRT stock performed over the past year?

Including dividends, TCRT returned -46.1% over the past year, against +11.3% for the S&P 500.

How many TCRT shares are sold short?

0M shares were sold short at the latest FINRA report, 24.00% of the float, or 1.0 days of average trading volume.

Who are Alaunos Therapeutics's competitors?

Companies most similar to Alaunos Therapeutics by business, industry and size include SYBX, TLPH, CRVO, AZTR, GNLX.

See a number that looks wrong?